cjc-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
The modern era or the modern period is considered the current historical period of human history. It was originally applied to the history of Europe and Western history for events that came after the classical antiquity and the Middle Ages, often from around the year 1500, like the Reformation's giving rise to Protestantism in Germany and elsewhere. Since the 1990s, it has been more common among historians to refer to the period after the Middle Ages and up to the 19th century as the early modern period. The modern period is today more often used for events from the 19th century until today. The time from the end of World War II (1945) can also be described as being part of contemporary history. The common definition of the modern period today is often associated with events like the French Revolution, the Industrial Revolution, and the transition from nationalism toward the liberal international order. The modern period has been a period of significant development in the fields of science, politics, warfare, and technology. It has also been an Age of Discovery and globalization. During this time, the European powers and later their colonies, strengthened their political, economic, and cultural colonization of the rest of the world. It also created a new modern lifestyle and has permanently changed the way people around the world live.
ImmTACs (Immune mobilising monoclonal T-cell receptors Against Cancer) are a class of bispecific biological drug being investigated for the treatment of cancer and viral infections which combines engineered cancer-recognizing TCRs with immune activating complexes. ImmTACs target cancerous or virally infected cells through binding human leukocyte antigen (HLA) presented peptide antigens and redirect the host's cytotoxic T cells to recognise and kill them. ImmTACs are fusion proteins that combine an engineered T Cell Receptor (TCR) based targeting system with a single chain antibody fragment (scFv) effector function. TCRs, like antibodies, constitute an important antigen recognition system within the immune system; but, whereas antibodies are restricted to targeting cell surface or secreted proteins TCRs can recognise peptides derived from intracellular targets presented by human leukocyte antigen (HLA). Naturally occurring TCRs are low affinity (0.18-387 micromolar range) 2-chain membrane receptors expressed on the surface of T cells. To produce stable, soluble, high affinity TCRs capable of being used as diagnostics and therapeutics the two TCR protein chains are stabilised through the introduction of a novel disulphide bond between the 2 constant domains and the affinity increased 1-5 million fold to low picomolar values through phage display affinity maturation. To provide the soluble, affinity enhanced TCR with a biological effector function the beta chain of the TCR is fused to an scFv antibody fragment specific for the CD3 T cell co-receptor, creating an ImmTAC.
== Selection and training == From early 1978 to 1980, support, training, and selection consisted of 3 phases, culminating latterly in 6 months/24 weeks training, with the first phase lasting as long as 11 weeks (the RLI's first phase was 6 weeks). Emphasis in selection depended on extreme physical fitness and aggression (running at an excess of 120 kilometres per week), mental strength in decision making and problem solving under extreme duress. The selection course consisted of a junior leader assessment in all areas concerning leadership. All Counter Operations Insurgency (COIN) battle drills were held in battle camps at Concession and Shamva. The pass rate among recruits amounted to only 30%. On passing out, recruits were deployed to one of 13 and latterly 14 troops (Troop company strength being 120 men; Mantle Mounted and November Troop being new additions in 1981). The Support Unit supported the Police in rural problem areas (latterly dissidents), as well as in urban emergencies. In November 1980, during the Entumbani I uprising, two sections of 60 men each from 5 Support Unit Troops (Mantle Echo, Mantle Charlie, Mantle Juliet, Mantle Hotel, Mantle Lima, 300 men in all), travelled from all over Zimbabwe to reach Bulawayo in 11 hours. Due to the Support Unit Troops being independent with their own vehicles, stores, ammunition, medical supplies, tents etc., they could deploy anywhere at a moment's notice all over Zimbabwe.
Sources: en.wikipedia.org
=== RNA sequences can be edited within cells === Messenger RNA precursors from a wide range of organisms can be edited before being translated into protein. In this process, non-encoded nucleotides may be inserted into specific sites in the RNA, and encoded nucleotides may be removed or replaced. RNA editing was first discovered within the mitochondria of kinetoplastid protozoans, where it has been shown to be extensive. For example, some protein-coding genes encode fewer than 50% of the nucleotides found within the mature, translated mRNA. Other RNA editing events are found in mammals, plants, bacteria and viruses. These latter editing events involve fewer nucleotide modifications, insertions and deletions than the events within kinetoplast DNA, but still have high biological significance for gene expression and its regulation.
In 1998, he voted for a bill that would have increased minimum sentencing for possessing a gun while committing a federal crime to ten years in prison, including nonviolent crimes such as marijuana possession. In 2005, Sanders voted for the Protection of Lawful Commerce in Arms Act. The purpose of the act was to prevent firearms manufacturers and dealers from being held liable for negligence when crimes have been committed with their products. As of 2016, he said that he has since changed his position and would vote for legislation to defeat this bill.
=== Design === Costume designer LJ Shannon "tried to stay as true to the [comics] lore as possible" in her designs. Each of the costumes are "utilitarian" with individual looks. Johns described Doctor Mid-Nite's as "[a] little steampunky" with canvas and leather and Hourman's as "a little more slick". Legacy Effects created a practical S.T.R.I.P.E. for use during filming.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.